NDA 21856/S-003

SUPPLEMENT APPROVAL
Fulfillment of Postmarketing Requirement

Takeda Pharmaceuticals North America, Inc.
One Takeda Parkway
Deerfield, IL 60015

Attention: Allison Villinski
Associate Director, Regulatory Affairs Strategy

Dear Ms. Villinski:

Please refer to your Supplemental New Drug Application (sNDA) dated May 27, 2010, received May 28, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Uloric (febuxostat tablets), 40 mg and 80 mg.

We acknowledge receipt of your amendments dated September 16, 2010, and January 25, 2011.

This “Prior Approval” supplemental new drug application proposes updating the ADVERSE REACTIONS section of the package insert with postmarketing safety information. It also provides for revisions to the CONTRAINDICATIONS, DRUG INTERACTIONS and CLINICAL PHARMACOLOGY SECTIONS of the package insert.

We have completed our review of this supplemental application, as amended and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling text for the package insert and the patient package insert and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements and any annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

Reference ID: 2898038
The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

We also note your submissions dated May 11, and 27, 2010, containing the final report for the following postmarketing requirement listed in the February 13, 2009, approval letter.

2. A drug-drug interaction trial to evaluate the effect of Uloric on the pharmacokinetics of a single, oral dose of theophylline.

<table>
<thead>
<tr>
<th>Final Protocol Submission Date:</th>
<th>April 30, 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial Start Date:</td>
<td>June 30, 2009</td>
</tr>
<tr>
<td>Trial Completion Date:</td>
<td>July 31, 2009</td>
</tr>
<tr>
<td>Final Report Submission Date:</td>
<td>May 31, 2010</td>
</tr>
</tbody>
</table>

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there is a postmarketing requirement listed in the February 13, 2009, approval that is still open.
PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sadaf Nabavian, Regulatory Project Manager, at (301) 796-2777.
Sincerely,

{See appended electronic signature page}

Sally Seymour, M.D.
Deputy Director for Safety
Division of Pulmonary, Allergy, and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SALLY M SEYMOUR
01/28/2011